Table 1

SLE subject characteristics

Short term n=9 (disease ≤2 years)Long term n=8 (disease ≥10 years)p Value
Age34.22±9.7241.23±8.040.134
Gender: % female100100na
Ethnicityns
 African American22%63%
 Hispanic44%37%
 Caucasian22%0%
 Asian12%0%
Education (years)14.67±2.412.29±6.050.296
SLEDAI2.22±2.053.25±3.20.437
Damage index0.33±0.51.25±0.710.007*
STAI36.44±11.7735±7.960.774
BDI10.78±11.166.88±3.720.346
Prednisone2.64±3.452.06±2.860.715
Anti-dsDNA titre*1.03±0.661.12±0.920.819
DNRAb titre0.30±0.150.29±0.090.774
Frequency DNRAb+66.7%54.5%0.858
Frequency anti-Ro+33.3%50%0.486
C3107.56±25117.13±19.90.4
C420.89±6.1124.5±13.240.47
Hydroxychloroquine55.6%87.5%0.183
Current disease-modifying antirheumatic drug use55.6%62.5%1.0
 Methotrexate22.2%00.265
 Cellcept11.1%50%0.131
 Azathioprine22.2%12.5%1.0
 Cyclophosphamide00na
Hypertension†11%38%0.294
Diabetes mellitus†00na
Smoking (ever)22.2%25%0.665
  • All data are reported as frequency (%) or as mean±SD. All data for medications (prednisone, hydroxychloroquine and immunosuppressive medications) refer to current use at the time of evaluation.

  • *Mean anti-dsDNA titre by ELISA in Diamond lab using same sera as the DNRAb titre.

  • †Current hypertension or diabetes mellitus requiring medication.

  • BDI, Beck Depression Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; STAI, State Trait Anxiety Inventory.